German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults

Johann Wolfgang Goethe University Hospital

Status and phase

Completed

Phase 4

Conditions

Lymphoma, Lymphoblastic

Treatments

Drug: Methotrexate

Drug: HDARAC

Drug: Cytarabine

Drug: Cyclophosphamide

Drug: Adriamycin

Drug: Vindesine

Drug: Asparaginase

Drug: G-CSF

Drug: Cladribine

Drug: VP16

Drug: Daunorubicin

Drug: Vincristine

Drug: Mercaptopurine

Procedure: CNS irradiation

Drug: Dexamethasone/Prednisolone

Drug: Thioguanine

Procedure: Mediastinal irradiation

Study type

Interventional

Funder types

Other

Identifiers

NCT00199017

GMALL04

Details and patient eligibility

About

This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to a protocol for acute lymphoblastic leukemia. Patients receive one year of intensive cyclical chemotherapy with additional prophylaxis for central nervous system (CNS) relapse by intrathecal therapy and cranial irradiation and mediastinal irradiation after induction chemotherapy.

Enrollment

75 estimated patients

Sex

All

Ages

15 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

T-lymphoblastic lymphoma (bone marrow [BM] involvement < 25%)
Aged 15-65 years (55-65 years if biologically younger)
Written informed consent

Exclusion criteria

Severe complications due to lymphoma or secondary disease
T-LBL as second malignancy or other active second malignancy
Cytostatic pretreatment of LBL (exception of emergency treatments)
Pregnancy
Severe psychiatric illness or other circumstances which may compromise cooperation of the patient or informed consent
Participation in other study interfering with study treatment